Glenmark Pharmaceuticals today announced the launch of antiviral drug Favipiravir (brand name FabiFlu) for the treatment of mild to moderate COVID-19 patients. It is a landmark development for COVID-19 patients in India. Glenmark has received manufacturing and marketing approval from India’s drug regulator, making FabiFlu the first oral Favipiravir-approved medication in India for the treatment of COVID-19. Favipiravir is backed by strong clinical evidence showing encouraging results in patients with mild to moderate COVID-19. The antiviral offers broad-spectrum RNA virus coverage with clinical improvement noted across age groups 20 to 90 years. Favipiravir has shown clinical improvement of up to 88% in COVID-19 mild to moderate COVID-19 cases. Favipiravir can be used in COVID-19 patients with co-morbid conditions such as diabetes and heart disease with mild to moderate COVID 19 symptoms.
Chairman and Managing Director of Glenmark Pharmaceuticals Ltd., Mr Glenn Saldanha said, this approval comes at a time when cases in India are spiralling like never before, putting tremendous pressure on our healthcare system. “We hope the availability of an effective treatment such as FabiFlu will considerably help assuage this pressure and offer patients in India a much needed and timely therapy option”, he added.
Glenmark’s Favipiravir for treatment of COVID-19
